EP0915849A2 - Procede de preparation de piperidines 3,3-bisubstituees - Google Patents

Procede de preparation de piperidines 3,3-bisubstituees

Info

Publication number
EP0915849A2
EP0915849A2 EP97937554A EP97937554A EP0915849A2 EP 0915849 A2 EP0915849 A2 EP 0915849A2 EP 97937554 A EP97937554 A EP 97937554A EP 97937554 A EP97937554 A EP 97937554A EP 0915849 A2 EP0915849 A2 EP 0915849A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
represents hydrogen
methyl
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97937554A
Other languages
German (de)
English (en)
Inventor
Mario Grugni
Roberto Rigolio
Karl Francis Erhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham SpA
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616417.3A external-priority patent/GB9616417D0/en
Priority claimed from GBGB9617594.8A external-priority patent/GB9617594D0/en
Application filed by SmithKline Beecham SpA, SmithKline Beecham Corp filed Critical SmithKline Beecham SpA
Publication of EP0915849A2 publication Critical patent/EP0915849A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to a novel process and to certain novel compounds prepared by such process.
  • European Patent Application, Publication Number 0673928 discloses certain compounds which are stated to have activity as specific antagonists of the human NK-3 receptor and in the treatment of diseases involving neurokinin B.
  • Example 19 of EP0673928 is the compound (+)-N- ⁇ ⁇ 3-[l-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-l-yl ⁇ -4-phenylpiperidin-4-yl ⁇ -N- methylacetamide, hereinafter also referred to as 'Compound V.
  • EP0673928 also discloses certain intermediates of formula (A), used in the preparation of Compound I, which intermediates are prepared by reduction and subsequent cyclisation of a nitrile intermediate of formula (B):
  • the present invention provides a process for preparing a compound of formula (I):
  • R2 represents hydrogen or benzoyl optionally substituted in the phenyi moiety with halogen, methyl or C 1.4 alkoxy; which process comprises cyclising a compound of formula (II):
  • the cyclisation of the compound of formula (II) is suitably carried out by treating the compound of formula (II) with glacial acetic acid, preferably in the presence of a catalytic amount of sulphuric acid, at any temperature providing a suitable rate of formation of the required product, usually at an elevated temperature such as a temperature in the range of 85°C to 105°C, for example at 100°C.
  • the above mentioned reduction may be carried out using any suitable reducing reagent or procedure, including c a complex metal hydride reagent or a borane reagent.
  • a preferred reducing agent is borane especially when complexed with a dialkysulphide, for example dimethyl sulphide.
  • the reduction is suitably carried our under the conditions conventionally used for the particular reduction method chosen.
  • aprotic solvent such as tetrahydrofuran
  • Ri is a protecting group, such as an acetyl or tetrahydropyran-2-yl group.
  • R2 is benzoyl.
  • the invention provides a process for the preparation of a compound of the above defined formula (III), which process comprises cyclising a compound of the above defined formula (II).
  • the reaction conditions for this process are as described above.
  • the invention provides a process for the preparation of a compound of the above defined formula (I) wherein R2 is hydrogen, which process comprises reducing a compound of the above defined formula (III).
  • the reaction conditions for this process are as described above.
  • the invention provides a process for the preparation of a compound of the above defined formula (I) wherein R2 represents benzoyloptionally substituted with halogen, methyl or C ⁇ .4 alkoxy, which process comprises acylating a compound of formula (I) wherein R2 represents hydrogen.
  • the reaction conditions for this process are as described above.
  • a suitable acylating agent is a benzoyl or an appropriately substituted benzoyl halide, preferably the chloride.
  • the compounds of formula (I) are useful as intermediates for the preparation of Compound I.
  • the compounds of formula (I) are preferably used in an activated form, for example in a tosylated or mesylated form.
  • the activated form of the compound of formula (I) is prepared using the appropriate conventional procedure depending upon its particular nature:
  • a mesylate is prepared by treating the compound of formula (I) with a mesyl haiide, for example mesylchloride, in an inert solvent such as dimethyl chloride.
  • the invention provides a process for the preparation of a compound of formula (IV): 98/05640
  • R2 is as defined in relation to (I)
  • R3 represents phenyl optionally substituted with halogen, methyl or C 1.4 alkoxy
  • R4 represents hydrogen or -CO- C ⁇ _4 alkyl
  • R5 represents C1.4 alkyl; which process comprises reacting a compound of the above defined formula (I), or an activated form thereof, with a compound of formula (V):
  • R3, R4 and R5 are as defined in relation to (IV), and thereafter optionally converting a compound of formula (IV) in to another compound of formula (IV).
  • the reaction between the compounds of formulae (TV) and (V) is suitably carried out in an aprotic solvent, preferably dimethylformamide at any temperature providing a suitable rate of formation of the final product, including temperatures such as room temperature, but usually at an elevated temperature.
  • reaction conditions depend upon the nature of the compound of formula (V):
  • R3 represents the said phenyl group and R4 represents hydrogen
  • the reaction is suitably carried out at ambient temperature.
  • R3 represents the said phenyl group and R4 represents -CO-C 1.4 alkyl
  • the reaction is usually effected at an elevated temperature such as a temperature in the range o 65°C to 100°C, for example 80°C, and preferably in the presence of a base such as a trialkylamine for example triethylamine.
  • -A- Suitable conversions of a compound of formula (IV) into another compound of formula (TV) includes the conversion of a compound of formula (IV) wherein R4 represents hydrogen into a compound of formula (IV) wherein R4 represents -CO- C ⁇ _4 alkyl by use of an approp ⁇ ate acylating agent; for example treatment with acetic anhydride smoothly converts R4 as hydrogen into R4 as acetyl
  • R3 represents phenyl optionally substituted with halogen, methyl or C 1.4 alkoxy
  • R4 is hydrogen
  • R5 is Ci .4 alkyl
  • R3 is phenyl
  • R4 is acetyl
  • R5 is methyl
  • the compounds of formula (IV) have at least one chiral centre
  • the present process provides either single isomer or racemic products depending upon the stereochemical nature of the starting mate ⁇ als.
  • the compounds of formula (I) can be separated into single isomers using known methodology (for example that disclosed n EP067928) which may then be used in the subsequent process steps disclosed herein.
  • the racemic products prepared by means of the present process can be separated into the component single isomers by using any conventional separation method, for example fractional crystallisation methods.
  • a further aspect the present invention also provides a novel, chiral high pressure liquid (HPLC) chromatographic method for resolving mixtures of optical isomers of compound (TV) which method is characterised m that the mobile phase comp ⁇ ses ethanol, hexane, tnfluoroacetic acid and and t ⁇ ethylamine, in particular 25% ethanol, 75% hexane, 0.5% tnfluoroacetic acid and 0.1% tnethylamine
  • a preferred HPLC column for use in the separation is a Daicel Chiral Cell OD column.
  • R ⁇ is as defined in relation to formula (I), with methylacrylate 98/05640
  • the reaction between the compounds of formula (VI) and methylacrylate is carried out in Triton B (40% in methanol) at any suitable temperature usually an elevated temperature such as the reflux temperature of the solvent.
  • R3 is as defined in relation to formula (V)
  • R4 a represents -CO-C 1.4 alkyl, especially acetyl
  • R5 represesnt C1.4 alkyl:
  • the compounds of formula (V) wherein R3 represents phenyl optionally substituted with halogen, methyl or C]__4 alkoxy, R4 represents hydrogen and R5 represents C1.4 alkyl are prepared from a compound of formula (VIII) wherein R3 and R4 a are as last defined, by removing the group R4 a using for example acid hydrolys, to provide a compound of formula (VII) which is then alkylated using conventional methods to give, after debenzylation of the ring nitrogen, the required compound of formula (V).
  • Any suitable alkylation method may be used, for example methylation is effected by initial formylation, by treatment with ethyl formate, followed by reduction with such as lithium aluminium hydride.
  • Debenzylation is usually effected by catalytic hydrogenolysis, using for example palladium on carbon in ethanol.
  • the compounds of formula (V) wherein R3 represents phenyl optionally substituted with halogen, methyl or C 1.4 alkoxy, R4 represents -CO- C 1.4 alkyl and R5 represents Ci .4 alkyl are prepared from the compound of formula (VIII) by first deprotecting the ring nitrogen, using the procedure described above, reprotecting as a BOC derivative to give the compound of formula (IX), alkylating the exocylic nitrogen of (IX) to give compound (X) using the procedure described above and finally isolating (V) in stabilisd form as the zinc chloride adduct.
  • the compounds of formula (VIII) known compounds prepared according to methods such as those in EP0673928.
  • the compounds of formula (VI) are known compounds or they are prepared according to methods disclosed for the preparation of such compounds, for example those disclosed in EP512901.
  • reaction mixture was quenched with 20% NH4CI, concentrated in vacuo and extracted with ether.
  • the organic phase was extracted with 0.5N NaOH; the aqueous phase was therefore acidified to pH 5 with IN HC1 and extracted with Et2 ⁇ .
  • the organic layer was d ⁇ ed over Na2SO4 and evaporated in vacuo to dryness to give
  • reaction mixture was quenched with 610 ml of 2N HC1, refluxed 2 hours and the solvent evaporated in vacuo to dryness.
  • the residue was treated with cone. NaOH and extracted with Et2 ⁇ ; the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • the residual oil was purified by gradient chromatography on 70-230 mesh silica gel, eluting with CH2C /MeOH (from 0 to
  • the title compound was prepared starting from 13.55 g (47 mmol) of 3-(3,4- dichIoro)pr ⁇ enyl-3-(3-hydroxypropyl)piperidine (compound of Description 3), 5.5 ml (47 mmol) of benzoyl chloride and 7 ml (50 mmol) of TEA and following the method described in EP 512901.
  • the crude product was purified by 70-230 mesh silica gel gradient column chromatography, eluting with CfoCb MeOH (from 0 to 5%) to afford 18 g of the title compound.
  • C21H23CI2NO2 M.W. 392.327 98/05640
  • reaction was quenched with 50 mi of water.
  • the reaction mixture was evaporated in vacuo to dryness; the residue was dissolved in EtOAc and washed with H2O; the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.
  • the crude product was purified on 70-230 mesh silica gel gradient column chromatography, eluting with CHiChMeOU (from 0 to 5%) to yield 7.5 g of the title compound as an oil.
  • Daicel Chiralcel OD column (10 ⁇ , 21.2 x 250 mm), using a flux of 10 ml/min with the UV detector fixed at 280 nm, eluting with a unique mobile phase consisting of
  • Controls of the samples were made by analytical HPLC on Daicel Chiralcel OD column (10 ⁇ , 4.6 x 250 mm) using a flux of 1 ml/min with the UV detector fixed at

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Procédé de fabrication d'un composé répondant à la formule (I): où R1 représente l'hydrogène ou un groupe de protection; où R2 représente l'hydrogène ou le benzoyle, substitués en option dans le groupe fonctionnel phénylique par un halogène, un méthyle ou un alkoxy C1-4; ledit procédé comprend la cyclisation d'un composé répondant à la formule (II): où R1 est tel qu'il est défini en rapport avec (I), afin d'obtenir un lactame cyclique ayant la formule (III): où R1 est tel qu'il est défini en rapport avec (I); le procédé consiste à réduire ensuite le composé ayant la formule (III) ainsi obtenu pour créer un composé ayant la formule (I) où R2 représente l'hydrogène; à la fin, on passe en option par une ou plusieurs étapes suivantes: (a) N-acyler les composés ayant la formule (I), où R2 représente l'hydrogène, pour obtenir un composé ayant la formule (I), où R2 représente le benzoyle et où le groupe fonctionnel phénylique est substitué en option par un halogène, un méthyle, ou un alkoxy C1-4; et (b) retirer tout groupe de protection.
EP97937554A 1996-08-05 1997-08-04 Procede de preparation de piperidines 3,3-bisubstituees Withdrawn EP0915849A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9616417.3A GB9616417D0 (en) 1996-08-05 1996-08-05 Process
GB9616417 1996-08-05
GBGB9617594.8A GB9617594D0 (en) 1996-08-22 1996-08-22 Process
GB9617594 1996-08-22
PCT/EP1997/004275 WO1998005640A2 (fr) 1996-08-05 1997-08-04 Procede de preparation de piperidines 3,3-bisubstituees

Publications (1)

Publication Number Publication Date
EP0915849A2 true EP0915849A2 (fr) 1999-05-19

Family

ID=26309818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97937554A Withdrawn EP0915849A2 (fr) 1996-08-05 1997-08-04 Procede de preparation de piperidines 3,3-bisubstituees

Country Status (3)

Country Link
EP (1) EP0915849A2 (fr)
JP (1) JP2000515534A (fr)
WO (1) WO1998005640A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
FR2787449B3 (fr) * 1998-12-15 2001-01-12 Sanofi Sa Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation
FR2787448B3 (fr) 1998-12-18 2001-01-12 Sanofi Sa Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9805640A3 *

Also Published As

Publication number Publication date
JP2000515534A (ja) 2000-11-21
WO1998005640A2 (fr) 1998-02-12
WO1998005640A3 (fr) 1998-05-22

Similar Documents

Publication Publication Date Title
US6809214B2 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
Berdini et al. A modified palladium catalysed reductive amination procedure
TW201213297A (en) Production method of intermediate compound for synthesizing medicament
NZ246768A (en) 3-azabicyclo[3.1.0]hexane intermediates useful in the preparation of quinoline antibiotics
RS49711B (sr) Postupak za dobijanje 1,4- dihidropiridina i jedinjenja koja se primenjuju u tom postupku
KR910007887B1 (ko) 1,4-디아자비사이클로[3.2.2]노난의 제조방법
WO1998005640A2 (fr) Procede de preparation de piperidines 3,3-bisubstituees
EP0906314A1 (fr) Resolution optique de composes de type narwedine
JP4874122B2 (ja) トルテロジンを得るための方法
EP0237899B1 (fr) Préparation de dérivés de la fluoroaniline
AU752444B2 (en) Novel stereoselective processes for the preparation of gabapentin analogues
US5463051A (en) Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
JPWO2006132424A1 (ja) ４（３ｈ）−キナゾリノン誘導体の製造方法
WO2007026373A2 (fr) Procede de preparation de rivastigmine
CA2287566A1 (fr) Derives de 9,10-diazatricyclo¬4.2.1.12,5|decane et 9,10-diazatricyclo¬3.3.1.12,6|decane presentant une activite analgesique
US7982054B2 (en) Process for the synthesis of N-[3-[(2-methoxyphenyl] sulfanyl] -2-methylpropyl] -3,4-dihydro-2H-1,5-benzoxathiepin-3-amine
IL91137A (en) Process for the enantiospecific synthesis of inter mediates for hexahydro-benzo Úd¾ naphtho Ú2,1-b¾ a zepines
JPH07103098B2 (ja) １‐置換（ｓ）‐および（ｒ）‐２‐アミノメチルピロリジン類の有効な立体保存的合成およびその中間体
RU2040526C1 (ru) Бициклические 1-аза-циклоалканы, смесь их изомеров или индивидуальные изомеры, или их фармакологически переносимые кислотно-аддитивные соли
AU622332B2 (en) New azetidines, their preparation and their application as intermediates for the preparation of compounds with antimicrobial activity
EP2125733A1 (fr) Procédé de préparation d'antagonistes des récepteurs ccr-5 utilisant des composés 1-cyclopropane-sulfonyl-pipéridinyl substitués en 4
WO2010004580A2 (fr) Procédé de préparation de dérivés d'indole
WO2000037443A1 (fr) Procede de preparation d'intermediaires et de derives de arylpiperidine carbinol
Pereira et al. Diastereoselective synthesis of chiral methyl 2-piperidin-2-ylpropanoates
JP2004149477A (ja) ベンゾシクロヘプテン誘導体の製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990129

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 19991102

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010308